Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ENVB

Enveric Biosciences Inc

Apr 25 • 04:00PM ET

0.9000

Dollar change -0.0340
Percentage change -3.64	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: PSIL VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.11	Insider Own	6.49%	Shs Outstand	7.29M	Perf Week	-4.05%
Market Cap	6.56M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	0.00%	Shs Float	6.82M	Perf Month	-15.09%
Income	-17.46M	PEG	-	EPS next Q	-0.78	Inst Own	6.71%	Short Float	1.40%	Perf Quarter	1.98%
Sales	0.00M	P/S	-	EPS this Y	70.41%	Inst Trans	-6.91%	Short Ratio	0.02	Perf Half Y	-50.55%
Book/sh	1.38	P/B	0.65	EPS next Y	34.86%	ROA	-134.87%	Short Interest	0.10M	Perf Year	-44.10%
Cash/sh	0.31	P/C	2.87	EPS next 5Y	-	ROE	-187.69%	52W Range	0.65 - 6.98	Perf YTD	-30.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	71.22%	ROI	-462.61%	52W High	-87.11%	Beta	0.82
Dividend TTM	-	Quick Ratio	1.29	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	38.67%	ATR (14)	0.11
Dividend Ex-Date	Apr 23, 2008	Current Ratio	1.29	EPS Y/Y TTM	40.69%	Oper. Margin	0.00%	RSI (14)	44.72	Volatility	7.43% 10.08%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	65.46%	Payout	-	Rel Volume	0.02	Prev Close	0.93
Sales Surprise	-	EPS Surprise	7.59%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	4.38M	Price	0.90
SMA20	-4.64%	SMA50	-14.08%	SMA200	-45.77%	Trades		Volume	88,594	Change	-3.64%

Apr-12-24 12:00PM	What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock (Zacks) +10.95%
Apr-01-24 10:53AM	ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 (InvestorPlace) -11.00%
Mar-26-24 07:00AM	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 (Business Wire)
Mar-19-24 07:00AM	Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease (Business Wire) +8.18%
Mar-12-24 07:00AM	Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets (Business Wire) -9.09%
02:04PM	Loading…
Feb-29-24 02:04PM	Why Is Enveric Biosciences (ENVB) Stock Up 120% Today? (InvestorPlace) +74.49%
07:00AM	Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds (Business Wire)
Feb-26-24 08:00AM	CORRECTION Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire) -13.12%
Feb-23-24 08:00AM	Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property (Business Wire) +15.29%
Feb-21-24 08:00AM	Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders (Business Wire)
Jan-03-24 08:00AM	Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series (Business Wire)
Dec-29-23 08:52AM	Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market (Business Wire) -16.67%
Dec-28-23 08:00AM	Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series (Business Wire) +19.77%
Dec-27-23 08:00AM	Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 (Business Wire)
Dec-20-23 08:00AM	Enveric Biosciences to Participate in Biotech Showcase 2024 During J.P. Morgan Week 2024 (Business Wire)
08:00AM	Loading…
Dec-05-23 08:00AM	Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds (Business Wire) -5.10%
Nov-29-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives (Business Wire) +5.44%
Nov-27-23 08:00AM	Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry (Business Wire)
Nov-24-23 08:00AM	Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023) (Business Wire)
Nov-13-23 04:01PM	Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results (Business Wire)
Oct-31-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin (Business Wire)
Oct-20-23 08:00AM	Enveric Biosciences to Present at the Centurion One 5th Global Summit (Business Wire) -5.45%
Oct-18-23 08:00AM	Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders (Business Wire)
Oct-11-23 08:00AM	Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit (Business Wire) -8.04%
Oct-03-23 08:00AM	Enveric Biosciences Announces its Psybrary Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates (Business Wire) +20.00%
Sep-27-23 08:00AM	Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry (Business Wire) +7.94%
Sep-20-23 08:00AM	Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates (Business Wire) -6.45%
Sep-18-23 08:00AM	Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 (Business Wire)
Sep-11-23 08:00AM	Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives (Business Wire) +7.66%
Sep-05-23 08:00AM	Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives (Business Wire)
08:00AM	Loading…
Aug-30-23 08:00AM	Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference (Business Wire)
Aug-28-23 11:04AM	Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs (Business Wire) +7.41%
Aug-24-23 08:00AM	Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB) (GlobeNewswire)
Aug-21-23 08:00AM	Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program (Business Wire) +7.44%
Aug-14-23 08:00AM	Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results (Business Wire)
Jul-24-23 08:00AM	Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 (Business Wire) -10.27%
Jul-17-23 08:00AM	Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 (Business Wire)
Jun-26-23 08:00AM	Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing (Business Wire) -5.84%
Jun-12-23 08:00AM	Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (Business Wire)
Jun-07-23 08:00AM	Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) (Business Wire) -11.23%
Jun-05-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates (Business Wire)
May-30-23 08:00AM	Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 (Business Wire) -14.58%
May-24-23 08:00AM	Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug (Business Wire) +52.70%
May-22-23 08:00AM	Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders (Business Wire) -16.38%
May-19-23 08:00AM	Enveric Biosciences to Participate in 2023 BIO International Convention in Boston (Business Wire)
May-18-23 08:00AM	Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin (Business Wire) +136.18%
May-15-23 09:25AM	Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire)
May-02-23 07:30AM	Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month (Business Wire)
Apr-10-23 07:30AM	Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference (Business Wire)
Apr-03-23 04:05PM	Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results (Business Wire)
Mar-23-23 07:30AM	Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 (Business Wire)
Mar-21-23 07:33AM	Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications (Business Wire)
Mar-14-23 07:30AM	Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery (Business Wire) -8.81%
Feb-28-23 07:30AM	Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.00%
Feb-23-23 07:33AM	Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Feb-22-23 07:33AM	Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference (Business Wire)
Feb-01-23 07:33AM	Enveric Biosciences to Present at the BIO CEO & Investor Conference (Business Wire)
Dec-21-22 07:30AM	Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023" (Business Wire)
Nov-28-22 07:30AM	Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders (Business Wire) -6.47%
Nov-16-22 07:30AM	Enveric Biosciences to Participate in A.G.P.s Virtual Biotech Conference (Business Wire) -5.00%
Nov-01-22 07:30AM	Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022 (Business Wire)
Oct-24-22 07:00AM	Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies (Business Wire) -6.91%
Oct-12-22 08:00AM	Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference (Business Wire)
Aug-31-22 07:30AM	Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 (Business Wire)
Jul-27-22 07:30AM	Enveric Biosciences Appoints New Independent Directors (Business Wire)
Jul-26-22 05:30PM	Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules (Business Wire) -8.53%
Jul-25-22 08:00AM	Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules (Business Wire) -28.36%
Jul-19-22 07:30AM	Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines (Business Wire)
Jul-14-22 12:15PM	Enveric Biosciences Announces Reverse Stock Split (Business Wire) -27.63%
Jul-13-22 07:30AM	Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio (Business Wire)
Jun-08-22 07:30AM	Enveric Biosciences to Participate in Upcoming Conferences in June 2022 (PR Newswire)
May-24-22 04:05PM	Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022 (PR Newswire) -11.65%
May-17-22 07:30AM	Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 (PR Newswire) +7.13%
May-11-22 07:30AM	Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders (PR Newswire) -14.22%
May-05-22 07:30AM	Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET (PR Newswire) -5.61%
May-03-22 05:13PM	Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock (PR Newswire)
Apr-29-22 08:35AM	KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Apr-25-22 08:35AM	KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th (GlobeNewswire)
Apr-06-22 07:30AM	Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022 (PR Newswire)
Mar-31-22 05:02PM	Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update (PR Newswire) -7.61%
Mar-29-22 07:30AM	Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application (PR Newswire) +5.79%
Mar-15-22 07:30AM	Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates (PR Newswire) +7.00%
Mar-03-22 07:30AM	Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022 (PR Newswire)
Mar-01-22 07:30AM	Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules (PR Newswire) +12.93%
Feb-17-22 07:30AM	Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress (PR Newswire)
Feb-15-22 04:05PM	Enveric Biosciences Announces Closing of $10 Million Public Offering (PR Newswire) -5.23%
Feb-11-22 08:30AM	Enveric Biosciences Announces Pricing of $10 Million Public Offering (PR Newswire) -49.03%
Feb-08-22 04:45PM	Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis (IPO-Edge.com)
07:30AM	Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate (PR Newswire)
Jan-18-22 07:30AM	Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders (PR Newswire) -7.57%
Jan-06-22 04:01PM	Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022 (PR Newswire) -6.27%
Dec-06-21 07:30AM	Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer (PR Newswire)
Nov-29-21 07:30AM	Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th (PR Newswire)
Nov-18-21 07:30AM	Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate (PR Newswire) -5.26%
Nov-09-21 07:09AM	Cannabis Sector Weekly Roundup (Market Exclusive)
Nov-08-21 07:30AM	Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF (PR Newswire)
Oct-26-21 07:30AM	Enveric Biosciences to Participate in Wonderland: Miami Conference (PR Newswire)
Oct-18-21 08:35AM	KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing (PR Newswire)
Oct-15-21 12:52PM	Enveric Biosciences on the Merger with MagicMed (Exec Edge)
Oct-11-21 09:25AM	KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th (PR Newswire)

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PASQUALONE FRANK	Director	Sep 15 '23	Buy	2.14	1,000	2,140	1,000	Sep 19 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENVB

Enveric Biosciences Inc

Upgrade your FINVIZ experience